Acyclovir Prophylaxis Against Varicella Zoster Virus Reactivation in Multiple Myeloma Patients Treated With Bortezomib-Based Therapies: A Retrospective Analysis of 100 Patients

Journal of Supportive Oncology

Volumn 10, Issue 4, 2012, Pages 155-159

  Swaika, Abhisek ^a,b   Paulus, Aneel ^a   Miller, Kena C ^a   Sher, Taimur ^a   Almyroudis, Nikolaos G ^a   Ball, Donna ^a   Wood, Margaret ^a   Masood, Aisha ^a   Lee, Kelvin ^a   Chanan Khan, Asher A ^a,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HERPES ZOSTER; HUMAN; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

ACYCLOVIR; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BORONIC ACIDS; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RETROSPECTIVE STUDIES; VIRUS ACTIVATION;

EID: 84862770542     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2011.10.006     Document Type: Article

References (33)

1. Dworkin R.H., Johnson R.W., Breuer J., et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007, 44(suppl 1):S1-S26.
2. Weaver B.A. The burden of herpes zoster and postherpetic neuralgia in the United States. J Am Osteopath Assoc 2007, 107(suppl 1):S2-S7.
3. Weaver B.A. Herpes zoster overview: natural history and incidence. J Am Osteopath Assoc 2009, 109(suppl 2):S2-S6.
4. Hambleton S., Gershon A.A. Preventing varicella-zoster disease. Clin Microbiol Rev 2005, 18(1):70-80.
5. Rusthoven J.J., Ahlgren P., Elhakim T., et al. Varicella-zoster infection in adult cancer patients. A population study. Arch Intern Med 1988, 148(7):1561-1566.
6. Jacobson D.R., Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. Semin Oncol 1986, 13(3):282-290.
7. Schutt P., Brandhorst D., Stellberg W., et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006, 47(8):1570-1582.
8. Nucci M., Anaissie E. Infections in patients with multiple myeloma. Semin Hematol 2009, 46(3):277-288.
9. Nucci M., Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009, 49(8):1211-1225.
10. Chanan-Khan A., Sonneveld P., Schuster M.W., et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008, 26(29):4784-4790.
11. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004, 127(2):165-172.
12. Kim S.J., Kim K., Kim B.S., et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma 2008, 8(4):237-240.
13. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359(9):906-917.
14. Tong Y., Qian J., Li Y., et al. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol 2007, 82(5):403-404.
15. Wu K.L., van Wieringen W., Vellenga E., et al. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. Haematologica 2005, 90(7):996-997.
16. Facon T., Mary J.Y., Hulin C., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370(9594):1209-1218.
17. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006, 367(9513):825-831.
18. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology, Multiple Myeloma (v1.2011) 2010, http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf.
19. Bladé J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102(5):1115-1123.
20. Pour L., Adam Z., Buresova L., et al. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma 2009, 9(2):151-153.
21. Vickrey E., Allen S., Mehta J., et al. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009, 115(1):229-232.
22. Hasegawa Y., Kawahara F., Nagai H., et al. Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy [in Japanese]. Rinsho Ketsueki 2009, 50(6):488-494.
23. Kropff M., Bisping G., Schuck E., et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007, 138(3):330-337.
24. Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006, 108(7):2165-2172.
25. Altun M., Galardy P.J., Shringarpure R., et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 2005, 65(17):7896-7901.
26. Kinchington P.R. Latency of varicella zoster virus; a persistently perplexing state. Front Biosci 1999, 4:D200-D211.
27. Basler M., Lauer C., Beck U., et al. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 2009, 183(10):6145-6150.
28. Adams J., Kauffman M. Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest 2004, 22(2):328-329.
29. Argyriou A.A., Iconomou G., Kalofonos H.P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008, 112(5):1593-1599.
30. Kaplowitz L.G., Baker D., Gelb L., et al. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. The Acyclovir Study Group. JAMA 1991, 265(6):747-751.
31. Mertz G.J., Jones C.C., Mills J., et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA 1988, 260(2):201-206.
32. Jancel T., Penzak S.R. Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia. Semin Hematol 2009, 46(3):230-247.
33. Dasanu C.A., Alexandrescu D.T. Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?. J Oncol Pharm Pract 2010, 16(4):266-268.